[Calusterone (7-beta, 17-alpha-dimethyltestosterone) in the palliative treatment of advanced breast cancer].
Results in palliative treatment of advanced breast cancer with a new androgen, calusterone, are discussed. Sixty post-menopausal patients with metastatic breast carcinoma were treated with 200 mg per day at least three months. The overall response was 28% (17/60); better results seemed to be achieved in advanced post-menopausal patients with osseous and cutaneous lesions. These results agree with those reported by the Cooperative Breast Cancer Group. No undesirable side-effects were observed and calusterone was well tolerated.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008777:Methyltestosterone / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008875:Middle Aged; D010166:Palliative Care; D013738:Testolactone / Q000627:therapeutic use; D013739:Testosterone / Q000627:therapeutic use
D013739:Testosterone; D013738:Testolactone; D008777:Methyltestosterone
Il calusterone (7-beta, 17-alfa-dimetiltestosterone) nel trattamento palliativo del carcinoma mammario in fase avanzata.